Navigation Links
Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule
Date:3/25/2009

--Company Now Has Until October 26, 2009 to Regain Compliance with $1.00 Minimum Bid Price Rule--

TUSTIN, Calif., March 25 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has received a letter from NASDAQ that provides Peregrine with an additional three months to regain compliance with the minimum bid price rule. Peregrine now has until October 26, 2009 to regain compliance with NASDAQ's $1.00 minimum bid price rule in order to remain listed on The Nasdaq Stock Market. This extension was granted as part of NASDAQ's recently announced temporary suspension of the minimum bid price and market value requirements for all NASDAQ-listed companies.

As previously announced, in December 2008 Peregrine received a letter from NASDAQ informing the company that the deadline for regaining compliance with the minimum bid price rule had been extended until July 27, 2009. This deadline is now extended until October 26, 2009, at which time Peregrine must evidence a closing bid price of $1.00 or more for a minimum of 10 prior consecutive trading days.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                        Media
    info@peregrineinc.com                            Barbara Lindheim
    (800) 987-8256                                   (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... ... ... For Immediate Release                Contact: ... Shows Young Women Seek Sex and Relationship Advice from their ...
(Date:8/18/2017)... New York, NY (PRWEB) , ... August 18, ... ... the launch of this summer’s edition of “Vision & Hearing,” advocating for active, ... The campaign focuses on resources available for individuals with hearing impairments and shares ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, a ... charity drive to generate community support for efforts to educate the local population on ... for all types of cancer. , Each day in America, roughly 4,600 new ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... planning services to communities in east Texas, is launching a regional charity effort ... , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... management and financial planning firm that serves residential and commercial clients in the ... charity drive to raise community support for the fight against cancer. , Founded ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... TEL AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. ... and immunology, today reports its financial results for the ... and achievements during the second quarter 2017 and to ... on multiple clinical development programs for the Company,s lead ... Phase 3 pivotal study with BL-8040 as novel stem ...
(Date:8/7/2017)... 2017 Insightin Health, provider of data-driven ... engagement, announced the selection of Michael Wood ... effective as of February 2017. In this role, Wood ... for our clients. Wood brings with him more ... business analytics within the healthcare industry. Wood formerly ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology: